Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10 000 women in Costa Rica

British Journal of Cancer

Volumn 89, Issue 7, 2003, Pages 1248-1254

  Wang, S S ^a   Schiffman, M ^a   Shields, T S ^a   Herrero, R ^b   Hildesheim, A ^a   Bratti, M C ^b   Sherman, M E ^a   Rodriguez, A C ^b   Castle, P E ^a   Morales, J ^b   Alfaro, M ^b   Wright, T ^c   Chen, S ^d   Clayman, B ^e   Burk, R D ^f   Viscidi, R P ^e  

^a NATIONAL CANCER INSTITUTE   (United States)

^b FUCODOCSA ^*  (Mexico)

^c Columbia University ^*  (United States)

^d INFORMATION MANAGEMENT SERVICES INC   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Cervical cancer; HPV; Predictors; Seroprevalence

Indexed keywords

VIRUS DNA;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; COSTA RICA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; RISK FACTOR; SEROPREVALENCE; UTERINE CERVIX CANCER; VIRUS INFECTION; VIRUS TYPING; WART VIRUS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CERVICAL INTRAEPITHELIAL NEOPLASIA; COHORT STUDIES; COSTA RICA; DNA, VIRAL; FEMALE; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; SEROEPIDEMIOLOGIC STUDIES; UTERINE CERVICAL NEOPLASMS;

EID: 0242361186     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601272     Document Type: Article

References (36)

1. Andersson-Ellstrom A, Dillner J, Hagmar B, Schiller J, Sapp M, Forssman L, Milsom I (1996) Comparison of development of serum antibodies to HPV-16 and HPV33 and acquisition of cervical HPV DNA among sexually experienced and virginal young girls A longitudinal cohort study. Sex Transm Dis 23: 234-238
2. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV (1995) Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 87: 796-802
3. Carter JJ, Koutsky LA, Hughes JP, Lee SK, Kuypers J, Kiviat N, Galloway DA (2000) Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 181: 1911-1919
4. Carter JJ, Koutsky LA, Wipf GC, Christensen ND, Lee SK, Kuypers J, Kiviat N, Galloway DA (1996) The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis 174: 927-936
5. Castle PE, Schiffman M, Gravitt PE, Kendall H, Fishman S, Dong H, Hildesheim A, Herrero R, Bratti MC, Sherman ME, Lorincz A, Schussler JE, Burk RD (2002a) Comparisons of HPV DNA detection by MY09/11 PCR methods. J Med Virol 68: 417-423
6. Castle PE, Shields T, Kirnbauer R, Manos MM, Burk RD, Glass AG, Scott DR, Sherman ME, Schiffman M (2002b) Sexual behavior, human papillomavirus type 16 (HPV 16) infection, and HPV 16 seropositivity. Sex Transm Dis 29: 182-187
7. Chua KL, Wiklund F, Lenner P, Angstrom T, Hallmans G, Bergman F, Sapp M, Schiller J, Wadell G, Hjerpe A, Dillner J (1996) A prospective study on the risk of cervical intra-epithelial neoplasia among healthy subjects with serum antibodies to HPV compared with HPV DNA in cervical smears. Int J Cancer 68: 54-59
8. De Sanjose S, Hamsikova E, Munoz N, Bosch FX, Hofmannova V, Gili M, Izarzugaza I, Viladiu P, Tormo MJ, Moreo P, Munoz MT, Ascunce N, Tafur L, Shah KV, Vonka V (1996) Serological response to HPV-16 in CIN-III and cervical cancer patients. Case - control studies in Spain and Colombia. Int J Cancer 66: 70-74
9. Dillner J, Kallings I, Brihmer C, Sikstrom B, Koskela P, Lehtinen M, Schiller JT, Sapp M, Mardh PA (1996) Seropositivities to human papillomavirus types 16, 18, or 33 capsids and to Chlamydia trachomatis are markers of sexual behavior. J Infect Dis 173: 1394-1398
10. Dillner J, Lehtinen M, Bjorge T, Luostarinen T, Youngman L, Jellum E, Koskela P, Gislefoss RE, Hallmans G, Paavonen J, Sapp M, Schiller JT, Hakulinen T, Thoresen S, Hakama M (1997) Prospective seroepidemiologic study of human papillomavirus infection as a risk factor for invasive cervical cancer. J Natl Cancer Inst 89: 1293-1299
11. Hagensee ME, Slavinsky III J, Gaffga CM, Suros J, Kissinger P, Martin DH (1999) Seroprevalence of human papillomavirus type 16 in pregnant women. Obstet Gynecol 94: 653-658
12. Heim K, Widschwendter A, Pirschner G, Wieland U, Awerkiew S, Christensen ND, Bergant A, Marth C, Hopfl R (2002) Antibodies to human papillomavirus 16 L1 virus-like particles as an independent prognostic marker in cervical cancer. Am J Obstet Gynecol 186: 705-711
13. Herrero R, Hildesheim A, Bratti C, Sherman ME, Hutchinson M, Morales J, Balmaceda I, Greenberg MD, Alfaro M, Burk RD, Wacholder S, Plummer M, Schiffman M (2000) Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst 92: 464-474
14. Herrero R, Schiffman M, Bratti C, Hildesheim A, Balmaceda I, Sherman ME, Greenberg M, Cardenas F, Gomez V, Helgesen K, Morales J, Hutchinson M, Mango L, Alfaro M, Potischman NW, Wacholder S, Swanson C, Brinton LA (1997) Design and methods of a population-based natural history study of cervical neoplasia in a rural province of Costa Rica: the Guanacaste project. Pan Am J Public Health 1: 362-374
15. Hildesheim A, Herrero R, Castle PE, Wacholder S, Bratti MC, Sherman ME, Lorincz AT, Burk RD, Morales J, Rodriguez AC, Helgesen K, Alfaro M, Hutchinson M, Balmaceda I, Greenberg M, Schiffman M (2001) HPV co-factors related to the development of cervical cancer: results from a population-based study in Costa Rica. Br J Cancer 84: 1219-1226
16. Ho GY, Burk RD, Klein S, Kadish AS, Chang CJ, Palan P, Basu J, Tachezy R, Lewis R, Romney S (1995) Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 87: 1365-1371
17. Kirnbauer R, Hubbert NL, Wheeler CM, Becker TM, Lowy DR, Schiller JT (1994) A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. J Natl Cancer Inst 86: 494-499
18. Kjaer SK, Chackerian B, van den Brule AJ, Svare EI, Paull G, Walbomers JM, Schiller JT, Bock JE, Sherman ME, Lowy DR, Meijer CL (2001) High-risk human papillomavirus is sexually transmitted: evidence from a follow-up study of virgins starting sexual activity (intercourse). Cancer Epidemiol Biomarkers Prev 10: 101-106
19. Kjellberg L, Wang Z, Wiklund F, Edlund K, Angstrom T, Lenner P, Sjoberg I, Hallmans G, Wallin KL, Sapp M, Schiller J, Wadell G, Mahlck CG, Dillner J (1999) Sexual behaviour and papillomavirus exposure in cervical intraepithelial neoplasia: a population-based case-control study. J Gen Virol 80: 391-398
20. Le Cann P, Touze A, Enogat N, Leboulleux D, Mougin C, Legrand MC, Calvet C, Afoutou JM, Coursaget P (1995) Detection of antibodies against human papillomavirus (HPV) type 16 virions by enzyme-linked immunosorbent assay using recombinant HPV 16 L1 capsids produced by recombinant baculovirus. J Clin Microbiol 33: 1380-1382
21. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348: 518-527
22. Nonnenmacher B, Hubbert NL, Kirnbauer R, Shah KV, Munoz N, Bosch FX, de Sanjose S, Viscidi R, Lowy DR, Schiller JT (1995) Serologic response to human papillomavirus type 16 (HPV-16) virus-like particles in HPV-16 DNA-positive invasive cervical cancer and cervical intraepithelial neoplasia grade III patients and controls from Colombia and Spain. J Infect Dis 172: 19-24
23. Nonnenmacher B, Kruger Kjaer S, Svare EI, Scott JD, Hubbert NL, van den Brule AJ, Kirnbauer R, Walboomers JM, Lowy DR, Schiller JT (1996) Seroreactivity to HPV16 virus-like particles as a marker for cervical cancer risk in high-risk populations. Int J Cancer 68: 704-709
24. Olsen AO, Dillner J, Gjoen K, Sauer T, Orstavik I, Magnus P (1996) A population-based case-control study of human papillomavirus-type-16 seropositivity and incident high-grade dysplasia of the uterine cervix. Int J Cancer 68: 415-419
25. Sasagawa T, Yamazaki H, Dong YZ, Satake S, Tateno M, Inoue M (1998) Immunoglobulin-A and -G responses against virus-like particles (VLP) of human papillomavirus type 16 in women with cervical cancer and cervical intra-epithelial lesions. Int J Cancer 75: 529-535
26. Shin HR, Lee DH, Herrero R, Smith JS, Vaccarella S, Hong SH, Jung KY, Kim HH, Park UD, Cha HS, Park S, Touze A, Munoz N, Snijders PJ, Meijer CJ, Coursaget P, Franceschi S (2003) Prevalence of human papillomavirus infection in women in Busan, South Korea. Int J Cancer 103: 413-421
27. Sigstad E, Lie AK, Luostarinen T, Dillner J, Jellum E, Lehtinen M, Thoresen S, Abeler V (2002) A prospective study of the relationship between prediagnostic human papillomavirus seropositivity and HPV DNA in subsequent cervical carcinomas. Br J Cancer 87: 175-180
28. Stone KM, Karem KL, Sternberg MR, McQuillan GM, Poon AD, Unger ER, Reeves WC (2002) Seroprevalence of human papillomavirus type 16 infection in the United States. J Infect Dis 186: 1396-1402
29. Strickler HD, Kirk GD, Figueroa JP, Ward E, Braithwaite AR, Escoffery C, Drummond J, Goebel B, Waters D, McClimens R, Manns A (1999) HPV 16 antibody prevalence in Jamaica and the United States reflects differences in cervical cancer rates. Int J Cancer 80: 339-344
30. Studentsov YY, Schiffman M, Strickler HD, Ho GY, Pang YY, Schiller J, Herrero R, Burk RD (2002) Enhanced enzyme-linked immunosorbent assay for detection of antibodies to virus-like particles of human papillomavirus. J Clin Microbiol 40: 1755-1760
31. Touze A, de Sanjose S, Coursaget P, Almirall MR, Palacio V, Meijer CJ, Kornegay J, Bosch FX (2001) Prevalence of anti-human papillomavirus type 16, 18, 31, and 58 virus-like particles in women in the general population and in prostitutes. J Clin Microbiol 39: 4344-4348
32. Viscidi RP, Ahdieh-Grant L, Clayman B, Fox K, Massad LS, Cu-Uvin S, Shah KV, Anastos KM, Squires KE, Duerr A, Jamieson DJ, Burk RD, Klein RS, Minkoff H, Palefsky J, Strickler H, Schuman P, Piessens E, Miotti P (2003) Serum immunoglobulin G response to human papillomavirus type 16 virus-like-particles in human immunodeficiency virus type 1 (HIV-1) positive and risk-matched HIV-1 negative women. J Inf Dis 187: 194-205
33. Wang ZH, Kjellberg L, Abdalla H, Wiklund F, Eklund C, Knekt P, Lehtinen M, Kallings I, Lenner P, Hallmans G, Mahlck CG, Wadell G, Schiller J, Dillner J (2000) Type specificity and significance of different isotypes of serum antibodies to human papillomavirus capsids. J Infect Dis 181: 456-462
34. Wideroff L, Schiffman M, Haderer P, Armstrong A, Greer CE, Manos MM, Burk RD, Scott DR, Sherman ME, Schiller JT, Hoover RN, Tarone RE, Kirnbauer R (1999) Seroreactivity to human papillomavirus types 16, 18, 31, and 45 virus-like particles in a case-control study of cervical squamous intraepithelial lesions. J Infect Dis 180: 1424-1428
35. Wideroff L, Schiffman M, Hoover R, Tarone RE, Nonnenmacher B, Hubbert N, Kirnbauer R, Greer CE, Lorincz AT, Manos MM, Glass AG, Scott DR, Sherman ME, Buckland J, Lowy D, Schiller J (1996) Epidemiologic determinants of seroreactivity to human papillomavirus (HPV) type 16 virus-like particles in cervical HPV-16 DNA-positive and-negative women. J Infect Dis 174: 937-943
36. Wideroff L, Schiffman M, Nonnenmacher B, Hubbert N, Kirnbauer R, Greer CE, Lowy D, Lorincz AT, Manos MM, Glass AG (1995) Evaluation of seroreactivity to human papillomavirus type 16 virus-like particles in an incident case-control study of cervical neoplasia. J Infect Dis 172: 1425-1430